Saphris Tablet
NDC Package 0456-2402-60
Package Information
Saphris (asenapine maleate) tablets is sAPHRIS is indicated for:Schizophrenia in adults [see Clinical Studies (14.1)]Bipolar I disorder [see Clinical Studies (14.2)]• Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age• Adjunctive treatment to lithium or valproate in adults• Maintenance monotherapy treatment in adults. This formulation utilizes a tablet delivery system. Marketed by Allergan, Inc., this product is identified by NDC 0456-2402 and is authorized under FDA application NDA022117.
Identification & Billing
- RxCUI: 1606337 - asenapine 2.5 MG Sublingual Tablet
- RxCUI: 1606337 - asenapine (as asenapine maleate) 2.5 MG Sublingual Tablet
- RxCUI: 1606490 - Saphris 2.5 MG Sublingual Tablet
- RxCUI: 1606490 - asenapine 2.5 MG Sublingual Tablet [Saphris]
- RxCUI: 1606490 - Saphris 2.5 MG (as asenapine maleate) Sublingual Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 0456 - Allergan, Inc.
- 0456-2402 - Saphris
- 0456-2402-60 - 6 CASE in 1 CARTON / 1 BLISTER PACK in 1 CASE (0456-2402-06) / 10 TABLET in 1 BLISTER PACK
- 0456-2402 - Saphris
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (0456-2402). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0456-2402-60 identifies a specific commercial package of 6 case in 1 carton / 1 blister pack in 1 case (0456-2402-06) / 10 tablet in 1 blister pack of Saphris, a human prescription drug labeled by Allergan, Inc.. This tablet is formulated for sublingual use and contains asenapine maleate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Allergan, Inc. on December 30, 2014. The current certification is valid through December 31, 2026.
How is this Allergan, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00456240260. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.